Dementia 2020 | Barcelona | Spain | Allied Conferences | Meetings

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences

Theme

Advances in Neurodegenerative Diseases and Brain Research

- Dementia 2020

Welcome Message

With absolute enthusiasm, we delight to welcome energetic researchers from all around the world to club together for the 14^th world congress on Dementia and Alzheimer’s disease scheduled on May 01-02, 2020 as Webinar.

Dementia 2020 is highlighted on the theme “Elucidating the latest advancements & cutting-edge research in Dementia and Alzheimer’s Disease” which encompasses keynote presentation, poster display, e-poster presentation, oral talks and exhibitions.

Dementia 2020 a fantastic dais for the great scientists, young researchers, doctors, nurses, academicians, neurosurgeons, neurologist and health professionals to undertake the International workshops, present your research, share experiences on all aspects of swiftly increasing field and thereby, exhibits your latest techniques and to enhance your career.

We hope that the event will inspire you, and results in unveiling knowledge and friendship, despite you will be able to enjoy the exotic and vibrant atmosphere.

Regards

Organizing committee

Dementia 2020

Scientific Sessions/Tracks

Session on Dementia:

Dementia is a term that encompasses a varietyof symptoms associated with cognitive impairment,such as forgetfulness. It is a symptom of a number of underlying diseases anddisorders of the brain. Alzheimer'sdisease is responsible for60-80% of dementia cases, the number expected to nearly double every twentyyears, reaching 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58% of all dementia patients lived incountries with low or moderate incomes, with that percentage expected toincrease to 63 percent by 2030 and 71 percent by 2050. By 2030, this situationis expected to have doubled, and by 2050, it will have tripled to 115 millionpeople.

RelatedAssociations:

Session on Alzheimer’s disease:

Alzheimer's disease is the beginning of moderate memory loss, which is caused by a lack ofability to carry out vital tasks. Alzheimer's disease is an irreversible,innovative braindisease that gradually impairs reminiscence and wondering abilities, aswell as the ability to perform even the most basic tasks. Alzheimer'sdisease is a condition inwhich the symptoms of dementia gradually increase over time. Reminiscence loss is mild in the earlystages of Alzheimer's, but with late-stage Alzheimer's, one loses the abilityto participate in sports and respond to others. Alzheimer's disease has nocure, but there are medications for the symptoms, and research continues.

RelatedAssociations:

Session on Neurodegenerative disorder:

The gradual loss of structure or function of neurons, including nerve cell death, is referred to asneurodegenerative. It can lead to the deterioration of the brain and nervesover time. Parkinson'sdisease, Normal PressureHydrocephalus, Huntington'sdisease, and Creutzfeldt-Jakob disease are some of the neurologicalconditions that cause dementia (CJD). These disorders are either Dementia-likeor have Dementia as a main symptom. Disorders such asParkinson's disease, Down syndrome, Creutzfeldt-Jakob disease, and Normal PressureHydrocephalus are caused by genetic factors. Physical conditions such as headinjury and traumatic brain injuries are among the other causes of dementia.

RelatedAssociations:

Session on Types of dementia:

Dementia is a nerve-related problem that results in severe brain damageand nerve disorders. Alzheimer'sdisease, lewy body dementia,front temporal dementia, Wernicke korsakoff syndrome, and other major syndromesare all present in this condition. Alzheimer is the common form of dementia. Wernicke korsakkof is a serious typeof dementia, and encephalopathy is another name for it. It's a thiamine (vitaminB1) deficiency. Parkinson'sdisease affects a person'sability to move, and tremors are common. Huntington's disease is a severeillness in which nerve cells gradually break down.

RelatedAssociations:

Session on Parkinson’s disease:

Dementiais a cognitive decline in thinking and reasoning that develops in the persondiagnosed with Parkinson's disease at least a year earlier. Nearly one millionpeople in the US are living with Parkinson's disease.The cause is unknown, and although there is presently no cure, there are treatmentoptions such as medicationand surgery to manage its symptoms.Hence this conference will provide a platform to discuss the problem.

RelatedAssociations:

Session on Vascular dementia:

The second most common dementia form is vascular dementia, whichdevelops after a stroke. However, several disorders such as thyroid problemsand vitamin deficienciescan cause dementia symptoms. Following strokes that obstructmajor brain blood vessels, changes in thought skills may occur unexpectedly invascular dementia. Minor differences in thinking will also develop over time asa result of a series of minor strokes or other diseases that involve smallerblood vessels, causing chronic harm. The degree of the blood vessel damage andthe part of the brain affected determine the symptoms of vascular dementia.Depending on the individual brain areas where blood flow is decreased, memory loss may or may not be a serioussymptom.

RelatedAssociations:

Session on Symptoms of Dementia:

Dementia is diagnosed by observing symptoms such as short-term memory loss,anxiety, depression, hearing loss, and headache. Seizures, epilepsy, heartbypass surgery, and depression are all medical disorders that can affectshort-term memory. Increased heart rate, shakiness,palpitations, chest pain, and a high risk of high blood pressure are allsymptoms of the condition. Anxiety disorders are characterized by hormonalshifts and a deficiency in the chemical messenger system. Anxiety attacksusually last 10 minutes, but they can last up to 30 minutes. Depression has theability to influence a person's psychological well-being as well as alter thephysical structures of the brain.

RelatedAssociations:

Session on Risk factor for dementia:

Dementia is a serious illness that is caused by age, heredity, andfamily history. Dementia mostly affects people over the age of60. However, it also affects young people in their 30s, 40s, and 50s. Whenpeople get older, their mental abilities deteriorate and dementia develops.These memory-related disorders are often caused bychromosomes, which are passed on from generationto generation. If someone in the family has a problem with disorder, it will showup in the next generation and cause dementia. It results in deterministicdementia in this situation.

RelatedAssociations:

Session on Clinical diagnosis of dementia:

Dementia evaluation is used to rule out diseases with common symptoms, such as depression and delirium,which are treatable. Dementia can be diagnosed using a variety ofmeasures, including the Mini Mental State Examination (MMSE), the Mental ScoreTest, and the Trail Making Test. The Memory, Speech, and Ability to Respond(MMSE) test consists of a series of exercises in which different difficultieswith memory, speech, and ability to respond areassessed. A blood test is also performed to check vitamin B12 and thyroidhormone levels, both of which may be responsible. MRI and CT scans of thebrain are used to screen for brain tumors and strokes in Vascular Dementia.Dementia Diagnosis is often misleading of various disorders such as Parkinson'sdisease, according toneurology meetings. As a result, the Dementia Society is on the lookout for newmethodologies and approaches for study in order to develop reliable diagnosticmethods.

RelatedAssociations:

Session on Prevention and treatment:

Maintaining normal body function, interacting with others, and engagingin certain exercise are the most important ways to avoid dementia. Another important way to avoid dementiais to eat a balanced diet. Limit the intake of fat-rich foodsand instead opt for fibrous foods. It will improve a person's chances of livinga life free of dementia. A treatment modality is a technique for treating apatient who is afflicted with a disease. Medical, psychological, andsociocultural approaches are the three primary approaches used in the treatmentmodalities. The most critical factor is that, in fact, no particular treatmentfor dementia is considered necessary. Combination therapy has provento be effective in the past.

RelatedAssociations:

Session on Neuroimaging biomarkers:

Mild Cognitive Impairment (MCI) with Neuroimaging-biomarkers allows for an early diagnosis of Alzheimer'sdisease in the preclinicalstages. In patients with late-onset Alzheimer's disease, researchers usedstructural and functional magnetic resonance imaging (MRI), advanced MRItechniques (diffusion tensor imaging, magnetic resonancespectroscopy, and perfusion), positron emission tomography with CSF protein levels, fluorodeoxyglucose, amyloidtracers, and other neurochemical tracers. These imaging biomarkers' complextests are used to predict disease development early on and improve theassessment of therapeutic efficacy in these diseases in future clinical trials.

RelatedAssociations:

Session on Role of Amyloid protein:

The plaque or neurofibrillary tangle-likestructure is formed by amyloid protein. Neurofibrillary tangles are twisted,insoluble fibersthat form between brain cells. This causes the neurons to degrade, resulting inthe symptoms of Alzheimer's disease. The formation of plaques between the nervecells in the brain causes Alzheimer'sdisease. Protein moleculesare broken down and removed in the healthy brain. In Alzheimer's disease, theirregular protein molecule triggers brain cell collapse.

RelatedAssociations:

Session on Memory disorder and neurologicproblems:

Memory loss is linked to a variety ofneurological conditions, including head trauma, brain tumours, and multiple sclerosis.There are a variety of explanations why someone may be having troubleremembering things. The word "neurological" comes from the medicalspecialty of neurology, which deals with issues involvingthe nervous system. The word "neuro" refers to the nervous system andnerves. Some neurologicaldisorders or disabilities are present from birth (congenital), while othersdevelop suddenly as a result of an accident or disease, such as a head injuryor stroke, or a brain or spine cancer.

RelatedAssociations:

Session on Dementia nursing:

Dementia nursing provides support for dementia patients while alsoassisting them in improving their quality of life. Also, include some guidancefor the person in charge of their treatment. Dementia nurses help dementiapatients improve their mentalhealth. Dementia nurses lookafter conditions such as trauma risk, persistent confusion, self-caredeficiency, and fall risk. The dementia patient's care intervention, orientclient, inspire caregiversto reorient, implement through positive reinforcement, and clarify clearlyEncourage others to be less critical of you.

RelatedAssociations:

Session on Alzheimer’s disease and Type2Diabetes:

Alzheimer'sdisease (AD) and type 2 diabetes mellitus (T2DM) are two majorage-related diseases with high morbidity and mortality rates.T2DM has been attributed to AD-type dementia by a few findings in human andanimal fashions. The interrelation units are indistinct despite epidemiologicaldating between T2DM and psychological vulnerability. The prevalence of proof inlongitudinal examinations with dissection affirmation has shown that vascularelements, rather than typical AD-type pathologies, underpin the psychologicaldecay often observed in self-revealed T2DM.

RelatedAssociations:

Session on Pathophysiology of Alzheimer:

Cholinergic dysfunction, amyloid/tau toxicity, and oxidativestress/mitochondrial dysfunction are all thought to play a role in Alzheimer'sdisease pathophysiology. Itis critical to identify accurate biomarkers in order to diagnose the disease'sexact pathophysiologyduring the pre-symptomatic stage. NREM sleep and a pathophysiology have abidirectional, causal relationship that can lead to Alzheimer's disease riskand progression.

RelatedAssociations:

Session on Drug development for dementia:

Drug creation for dementia is atime-consuming process. The first dementia drug was approved in 2003, and therehas been no other approval for dementia drug production since then. Thenational institute of ageing is conducting new dementia studies using amyloid,tau, and neurodegenerative conditions. The more stages of dementia aregenerated by this framework. Dementia clinical trials are beneficial inunderstanding the function of positron emission tomography. Drug research is mostly focused onrepurposing medications,which suggests that a drug has already been used for several differentconditions and is now being used for dementia with certain chemicalmodifications.

RelatedAssociations:

Session on Gene therapy in dementia:

Recent advances in gene therapy-based approaches, especially inrecombinant adeno-associated viruses (rAAVs), have given researchers new toolsto investigate Alzheimer's disease and other neurodegenerative disorders. Gene therapymethods have also emerged as a promising treatment option for these diseases inhumans. The ApoE4 protein, which has been linked to an increased risk of Alzheimer'sdisease, has been shown toprevent a peptide clearance and encourage an aggregation into plaque. Novel therapeutics for theprevention and treatment of this disease can be studied using several mousemodels with variations in the APOE gene.

RelatedAssociations:

Session on Bioinformatics approach fordementia:

The advent of bioinformatics can be used to manage and analysedata generated by today's high-throughput research technologies, paving the wayfor new discoveries in the field of neurodegenerative diseases. Epigenomics hasbeen stated to have very little published data. The information is said to havecome from high-throughput methods used in brain screening. These data will helpfuture researchers understand and plan their experiments. The actual data iscompared with the real data, and the findings are interpreted, and Data Mining plays an important role in thedisorder prediction. Transcriptomics and Proteomics experiments have also been conductedin order to provide solutions to the problems.

RelatedAssociations:

Session on Translational animal model:

Animal models are widely used by researchers to discover new medicinesand test them in animals such as mice. Only the Alzheimer'sdiseases are supported inthe animal model, and the front temporal diseases are closely linked. As aresult, focus your research on Alzheimer's disease. Amyloidopathy and tauopathycan be seen in Alzheimer's patients. Despite the fact that the anatomy of a mouse differs from that of ahuman, the participant importance is increased. Several companies havespecialised in antibodiesthat inhibit neurodegenerative in these mouse models as a result ofthis.

RelatedAssociations:

Session on Clinical trial and case report:

The aim of dementia research is to create a drug that can help themrecover from their condition. It can be found all over the world. Clinicalstudies are conducted to determine whether or not this procedure is effectivefor patients. There is no cure for dementia without clinical trials and caregivers. Cholinesterase inhibitors are medications thatare used to treat mild to severe dementia. These medications can aid in thetreatment or suppression of the problem. There is no standard treatment fordementia, but there are certain steps that can be taken to keep the patient's mental state stable.

RelatedAssociations:

Session no Neuroscience:

Neuroscience is the study of nervous system. It is an interdisciplinary science that combines anatomy, physiology, developmental biology, molecular biology, cytology, mathematical modeling and computer science to understand the emergent properties and fundamentals of neurons and neural circuits. Due to advances in electrophysiology, molecular biology and computational neuroscience, the study of the nervous system raised significantly.

Related Associations:

Market Analysis

Someone somewhere on the world causes dementia at regular interval. In 2015, there were an estimated 46.8 million people living with dementia, and this figure is projected to rise to near 50 million in 2017. This number will practically twofold at regular intervals, arriving at 75 million out of 2030 and 131.5 million out of 2050. A large portion of the expansion will take place in developing countries. Effectively 58% of individuals with dementia live in low-and center pay nations; however by 2050 this will ascend to 68%. The quickest development in the old populace is occurring in India, China and their south Asian and western Pacific neighbors.

Statistics maturing is an all-encompassing procedure that reflects the advancements in medical services over the course of the last century. Many are presently living longer and more beneficial lives thus the total populace has a more prominent extent of more seasoned individuals. Despite the fact that there is a growing awareness of cases that begin before the age of 65, dementia mostly affects older people.

Every year, more than 9.9 million new cases of dementia are diagnosed around the world, implying one new case every 3.2 seconds.

The World Alzheimer Report 2015 updates ADI's global assessments of dementia's prevalence, incidence, and costs, which are based on reliable surveys. The report provides key recommendations for establishing a global dementia-related activity scheme. The study also includes an examination of the evidence for and against late trends in the prevalence and incidence of dementia over time, as well as an investigation of dementia's broader cultural impact.

Past Conference Report

Triumphant completion of 13^th World Congress on Dementia and Alzheimer's Disease, Paris, France on September 16-17, 2019

A further conference on Dementia has been successfully completed; we must thank our organizing committee members, keynote speakers, plenary speakers, our young scientists and our delegates for making this dementia congress as a grand success on a pertinent theme of “Exploring the Challenges in the Era of Dementia Research and Care”.

We are glad that our attendees had obtained the updated information in the field of dementia; their participation in this conference has been a major step in their career. Some highlighted sessions of Dementia 2019 include Dementia, Alzheimer’s disease, Parkinson’s disease, Neurodegenerative Diseases, Vascular dementia, Neuropharmacology, Neuroepigenetics etc.

Organizing committee of Dementia 2019 was

Alain Fymat| International Institute of Medicine and Science | USA

Alberto Musto | Eastern Virginia Medical School | USA

Santiago Restrepo | American University Corporation | Colombia

Ian Martins | Edith Cowan University | Australia

George N. Shilau | Republican Clinic Medical Center | Russia

Dario Furnari | University of Exeter | United Kingdom

Notable Participants of Dementia 2019

Jan Ricny | National Institute of Mental Health | Czech Republic

Veronica Reaelli | Neurological Institute Carlo Besta | Italy

Sandra Garrido | Western Sydney University | Australia

Zdenka Kristofikova | National Institute of Mental Health | Czech Republic

Elena Vasenina | Russian Medical Academy of Postgraduate Education | Russia

Levin Oleg | Russian Medical Academy of Postgraduate Education | Russia

Bogolepova Anna | Russian National Research Medical University. N.I. Pirogov | Russia

Katunina Elena | Russian National Research Medical University. N.I. Pirogov | Russia

Parfenov Vladimir | MGMU them. I.M. Sechenov | Russia

Preobrazhenskaya Irina | MSMU them. I.M. Sechenov | Russia

Koberskaya Nadezda | MSMU them. I.M. Sechenov | Russia

Mkhitaryan Elen | Russian National Research Medical University. N.I. Pirogov | Russia

Emelin Andrey | Military Medical Academy named after S.M. Kirov | Russia

Lobzin Vladimir | Military Medical Academy named after S.M. Kirov | Russia

Soldatkin Viktor | Department of Psychiatry and Narcology FPK and PPS | Russia

Marcel Germain | Diex Recherche | Canada

Ukharskaia Ekaterina | LLC Merz Pharma | Russia

Shatrova Vera | LLC Merz Pharma | Russia

Azza A Ali | Al Azhar University | Egypt

For this successful completion we should mainly thank our media partners for associating with us.

With the grand success of Dementia 2019 AAC proud to announce 14th World Congress on Dementia and Alzheimer's Disease, Dubai on December 08-09, 2020.